Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Endo’s shown it’s willing to spend. But with Salix gone, what’s left worth buying?

March 17, 2015
Life sciences
As Endo showed last week with its failed $10 billion bid for North Carolina’s Salix, it’s willing to shell out some serious dough if the right target comes along. The question is, what’s left?
 
Not much in that price bracket, the way Morningstar analyst Michael Waterhouse sees it. Salix was “kind of that last low-hanging fruit sitting out there,” he told Bloomberg. “There are still a lot of small companies out there that they’ll continue to look for but it’s definitely becoming a much more crowded buyers’ market.”
 
Indeed, after losing Salix to Valeant –which ponied up $173-per-share in cash, compared with Endo’s $175-per-share in cash and stock–the Ireland-based company may have to duke it out with other dealmakers down the line. In addition to serial buyer Valeant, companies like Shire and Pfizer are reportedly still on the hunt.
 
The good news for Endo, though, is that it’s “casting a pretty wide net,” Piper Jaffray analyst David Amsellem told the news service. The company could try building out its pain-management business–perhaps with a buyout of $750 million partner BioDelivery Sciences, or, further down the line, a merger with fellow Irish countryman Mallinckrodt, worth about $15 billion. Another target could be $3 billion Impax Labs, Gabelli & Co. analysts suggested–as could smaller players around the globe.
 
“If you looked not just in North America but overseas, there are many private companies and many small companies that many in the broader investment community have never heard of,” Amsellem said. “But you can rest assured that Endo has heard of them.”
 
That’s not necessarily surprising, considering CEO Rajiv De Silva’s resume. The helmsman previously served as president at Valeant, and since joining Endo he seems to have taken a page from that company’s playbook. De Silva struck up a string of deals last year, including pickups of Paladin Labs–which helped it complete its tax inversion–and Canada’s Auxilium, a $2 billion-plus tie-up that closed this January.
 
By Carly Helfand
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach